Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance-Reference-Cited by-同舟云学术

Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance

Published:2022-05 Issue:24 Volume:40 Page:3305-3312
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Nasreen Sharifa,Calzavara Andrew,Buchan Sarah A.,Thampi Nisha,Johnson Caitlin,Wilson Sarah E.,Kwong Jeffrey C.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference51 articles.

1. Health Canada. Drug and vaccine authorizations for COVID-19: List of applications received: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/applications.html [accessed 23 November 2021].

2. Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html#wb-auto-4 [accessed 23 November 2021].

3. Health Canada. Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications Ottawa, ON: Government of Canada; 2021 [Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/authorization/list-drugs.html [accessed 19 March 2021].

4. Ontario Agency for Health Protection and Promotion (Public Health Ontario). COVID-19 viral vector vaccines and rare blood clots – vaccine safety surveillance in action Toronto, ON: Queen’s Printer for Ontario; 2021 [Available from: https://www.publichealthontario.ca/-/media/documents/ncov/vaccines/2021/07/covid-19-viral-vector-vaccines-rare-blood-clots.pdf?sc_lang=en [accessed 6 June 2021].

5. Medicines and Healthcare products Regulatory Agency (MHRA). Coronavirus vaccine - weekly summary of Yellow Card reporting [Internet]. London (UK): Department of Health and Social Care 2021 [Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting [accessed, 26 October 2021].

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network;Vaccine;2024-07

2. Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring in South Korea;Journal of Health Informatics and Statistics;2024-05-31

3. COVID-19 vaccination safety and associated health care utilization among adults with inflammatory bowel disease – a population-based self-controlled case series analysis;BMC Gastroenterology;2024-05-30

4. JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022—2023;Sexually Transmitted Diseases;2024-04-19

5. The association of peritoneal dialysis and hemodialysis on mitral and aortic valve calcification associated mortality: a meta-analysis;Scientific Reports;2024-02-27